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S U M M A R Y
Objectives: The epidemiological and clinical determinants of hepatitis delta virus (HDV) infection in Sub-
Saharan Africa are ill-deﬁned. The prevalence of HDV infection was determined in HIV/hepatitis B virus
(HBV) co-infected individuals in rural Tanzania.
Methods: All HBV-infected adults under active follow-up in the Kilombero and Ulanga Antiretroviral
Cohort (KIULARCO) were screened for anti-HDV antibodies. For positive samples, a second serological
test and nucleic acid ampliﬁcation were performed. Demographic and clinical characteristics at
initiation of antiretroviral therapy (ART) were compared between anti-HDV-negative and -positive
patients.
Results: Among 222 HIV/HBV co-infected patients on ART, 219 (98.6%) had a stored serum sample
available and were included in the study. Median age was 37 years, 55% were female, 46% had World
Health Organization stage III/IV HIV disease, and the median CD4 count was 179 cells/ml. The prevalence
of anti-HDV positivity was 5.0% (95% conﬁdence interval 2.8–8.9%). There was no signiﬁcant predictor of
anti-HDV positivity. HDV could not be ampliﬁed in any of the anti-HDV-positive patients and the second
serological test was negative in all of them.
Conclusions: No conﬁrmed case of HDV infection was found among over 200 HIV/HBV co-infected
patients in Tanzania. As false-positive serology results are common, screening results should be
conﬁrmed with a second test.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Worldwide, 5% of individuals with chronic hepatitis B virus
(HBV) infection have serological evidence of exposure to hepatitis
delta virus (HDV).1 HBV/HDV co-infected individuals generally
have more severe liver disease than HDV-uninfected individuals.* Corresponding author. Tel.: +41 31 632 25 25.
E-mail address: gilles.wandeler@ispm.unibe.ch (G. Wandeler).
http://dx.doi.org/10.1016/j.ijid.2016.03.011
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Only limited data on HDV infection are available from Sub-
Saharan Africa (SSA); prevalence estimates range from zero in
hepatitis B surface antigen (HBsAg)-positive individuals in
Mozambique to 53% in the Central African Republic.2,3 The aim
of this study was to determine the prevalence, as well as the main
epidemiological and clinical determinants, of HDV infection in
HIV/HBV co-infected individuals in rural Tanzania. To estimate
the proportion of false-positive HDV screening tests, all positive
samples were retested with a second serological assay and nucleic
acid ampliﬁcation.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Serology results for 11 patients with a positive anti-HDV screening testa
Patient DiaSorin OD DiaPro ratio
1 0.87 0.49
2 0.62 0.18
3 0.65 0.19
4 0.81 0.21
5 0.87 0.18
6 0.71 0.20
7 0.60 0.19
8 0.83 0.21
9 0.89 0.18
10 0.91 0.27
11 0.73 0.19
HDV, hepatitis delta virus; OD, optical density.
a Positive result: DiaSorin OD <0.9, DiaPro ratio (threshold/OD) >0.9.
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The study was conducted within the Kilombero and Ulanga
Antiretroviral Cohort (KIULARCO) in Ifakara, Tanzania.4 All HIV/
HBV-co-infected adults (15 years of age) with at least a baseline
and one follow-up visit between January 2013 and December 2014,
and who started antiretroviral therapy (ART) before December
2014, were included. All participants gave written informed
consent. Ethical approval was obtained from the Ifakara Health
Institute institutional review board and from the National Institute
for Medical Research of Tanzania.
Serum HBsAg was tested using a rapid test (Abon Biopharm,
Hangzou, China). The ETI-AB-DELTA-2 test (DiaSorin, Brussels,
Belgium) was used to screen for anti-HDV antibodies; results
were considered positive when the optical density (OD) was
<0.9. A second serological test was used as conﬁrmation (HDV-
Ab kit; DiaPro, Milan, Italy, used on an ETI-Max (DiaSorin)
platform). The result was considered negative when the ratio
(threshold/OD) was <0.9. For the measurement of HDV viral
load, total nucleic acids were puriﬁed from plasma (Qiagen EZ1
DSP kit), and cDNA (High Capacity cDNA Reverse Transcription
Kit; Applied Biosystems) was subjected to real-time PCR
according to Ferns et al.,5 with minor modiﬁcations. The
detection limit was 1000 genome equivalents per milliliter of
plasma.
Anti-HDV prevalence was described with a 95% conﬁdence
interval (CI). Fisher’s exact test and the Wilcoxon rank sum test
were used to compare individual characteristics at ART start
between anti-HDV-positive and negative individuals. AnalysesTable 2
Baseline characteristics by anti-HDV screening result
Baseline characteristics HDV screening test result 
Anti-HDV non-reactive (n =
Sex, n (%)
Female 114 (54.8) 
Male 94 (45.2) 
Age, years, median (IQR) 37 (31–44) 
BMI, kg/m2, median (IQR) 20.3 (18–23) 
CD4 cell count, cells/ml, median (IQR) 174 (66–275) 
ALT, IU/ml, median (IQR) 23.0 (11.0–39.6) 
eGFR, ml/min, median (IQR) 132.3 (110.6–146.1) 
Initial ART regimen (%) 
3TC/D4T/NVP 39 (18.8) 
3TC/AZT/EFV 63 (30.3) 
XTC/TDF/EFV 77 (37.0) 
Other 29 (13.9) 
HDV, hepatitis delta virus; IQR, interquartile range; BMI, body mass index; ALT, alanine 
formula; ART, antiretroviral therapy; 3TC, lamivudine; D4T, stavudine; NVP, nevirapine;
a Using ETI-AB-DELTA-2 (DiaSorin).were done using SAS version 9.3 software (SAS Institute, Cary, NC,
USA).
3. Results
Of 222 HBsAg-positive patients on ART, 219 (98.6%) had a
stored sample available for HDV serology. The median age of the
patients was 37 years, 55% were female, 46% had World Health
Organization stage III/IV HIV disease, and the median baseline CD4
count was 179 cells/ml.
The prevalence of anti-HDV antibody-positivity was 5.0% (11/
219, 95% CI 2.8–8.9%) with the screening test. In all positive
samples, the OD ranged between 0.60 and 0.91 (median 0.81,
interquartile range (IQR) 0.65–0.87), while the positive controls
had OD values between 0.05 and 0.09. Among 11 anti-HDV-
positive samples, none was positive with the second anti-HDV test
(negative controls all had a DiaPro ratio (threshold/OD) <0.9;
Table 1). HDV RNA could not be ampliﬁed in any of the patients
with a positive screening test. Positive real-time PCR results of
spiked internal RNA controls conﬁrmed that HDV RNA-negative
results were true negatives (data not shown).
The age and sex distribution, as well as median body mass
index, CD4 cell count, and alanine aminotransferase levels were
similar between anti-HDV-positive and -negative individuals
(Table 2). The estimated glomerular ﬁltration rate was slightly
lower in HDV-positive individuals compared to HDV-negative
individuals (p = 0.05).
4. Discussion
In this cohort of over 200 HIV/HBV co-infected individuals in
rural Tanzania, no conﬁrmed case of active HDV infection was
found. Five percent of the patients had a positive anti-HDV
antibody screening test, but the second serology and nucleic acid
ampliﬁcation were negative in all of them. As no demographic or
clinical predictor of anti-HDV false-positivity was identiﬁed, these
results suggest that weakly positive (OD values 0.1–0.9) anti-HDV
screening results should be conﬁrmed with an additional test.
There appear to be no published data on HDV prevalence in
Tanzania at the current time. In line with the results of this study,
reports from neighboring countries Mozambique and Burundi
have shown the absence of HDV infection, whereas an anti-HDV
antibody prevalence of 53% has been described in the Central
African Republic.2,3,6 As there seem to be large differences in HDV
prevalence across and even within countries, further research is
needed to improve our knowledge on HDV infection in SSA.p-Value
 208) Anti-HDV reactive (n = 11)a
5 (45.5) 0.55
6 (54.6)
37 (30–44) 0.77
20.8 (17–23.5) 0.98
214 (84–337.5) 0.69
26.6 (13.7–54.0) 0.36
115.4 (105.1–124.4) 0.05
0.18
0
5 (45.4)
6 (54.6)
0
aminotransferase; eGFR, estimated glomerular ﬁltration rate based on the CKD-EPI
 AZT, zidovudine; EFV, efavirenz; XTC, lamivudine or emtricitabine; TDF, tenofovir.
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positive result. Thus, the cut-off recommended by the manufac-
turer appears inappropriate in the present study setting. Unfortu-
nately it was not possible to calculate the speciﬁcity of the HDV
antibody screening test as patients with a negative result were not
tested with the second serology. However, if the patients with
a negative screening test were all truly HDV-uninfected, the
speciﬁcity would be 95% (95% CI 91–97%). Although no predictor of
anti-HDV false-positivity was identiﬁed in this cohort, the power
to detect such a difference was very limited. Govindarajan et al.
suggested that lipemic serum or the presence of rheumatoid factor
were associated with false-positive anti-HDV immunoassay
results.7 Unfortunately it was not possible to test these hypotheses
as data on lipids were unavailable.
In summary, HDV infection was found to be rare in HIV/HBV co-
infected individuals in rural Tanzania. To avoid the over-
estimation of HDV prevalence, future studies should conﬁrm
serological results with a second test, especially in patients with a
weakly positive ETI-AB-DELTA-2 test result.
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